Core Insights - Amedisys reported revenue of $570.79 million for Q4 2023, a year-over-year increase of 1.6% and an EPS of $0.94, down from $1.16 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $564.85 million by 1.05%, while the EPS fell short of the consensus estimate of $1.04 by 9.62% [1] Revenue Breakdown - Net Service Revenue from Home Health was $358.90 million, surpassing the average estimate of $356.95 million, reflecting a year-over-year increase of 4.8% [2] - Net Service Revenue from High Acuity Care was $5.90 million, matching the average estimate of $4.90 million, with no year-over-year change [2] - Net Service Revenue from Hospice reached $206 million, exceeding the average estimate of $200.35 million, representing a year-over-year increase of 4.3% [2] Stock Performance - Amedisys shares have returned -1.1% over the past month, contrasting with the Zacks S&P 500 composite's increase of 3% [2] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance against the broader market in the near term [2]

Amedisys (AMED) came out with quarterly earnings of $0.94 per share, missing the Zacks Consensus Estimate of $1.04 per share. This compares to earnings of $1.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -9.62%. A quarter ago, it was expected that this home health care and hospice services provider would post earnings of $1.08 per share when it actually produced earnings of $0.98, delivering a surprise of -9.26%.Over the ...

| --- | --- | |-------|-------------------------------------------------------------------------| | | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | FORM 10-K | (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-24260 AMEDISYS, INC. (E ...

Exhibit 99.1 AMEDISYS REPORTS FOURTH QUARTER AND YEAR-END 2023 FINANCIAL RESULTS BATON ROUGE, Louisiana (February 21, 2024) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2023. Three-Month Periods Ended December 31, 2023 and 2022 ◦ Net service revenue increased $8.8 million to $570.8 million compared to $562.0 million in 2022. Prior year included $15.9 million of net service revenue from our personal care business which was diveste ...

The market expects Amedisys (AMED) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they mi ...

BATON ROUGE, La., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), a leading provider of home health, hospice and high-acuity care in the home, is now offering advanced molecular testing to its care centers nationwide. This innovative collaboration with Patient Choice Laboratories utilizes molecular testing for the swift and precise identification of pathogens in urine, respiratory and wound infections. By leveraging the latest in diagnostic technology, Amedisys aims to improve the quality of ...

Financial Performance - Net service revenue for the three months ended September 30, 2023, was $556.2 million, a slight decrease of 0.3% compared to $558.0 million for the same period in 2022[21] - Operating income for the three months ended September 30, 2023, increased to $42.2 million, up 3.3% from $38.9 million in the same period last year[21] - Net income attributable to Amedisys, Inc. for the three months ended September 30, 2023, was $26.0 million, compared to $25.6 million for the same period in 2022, reflecting a growth of 1.4%[21] - Basic earnings per share for the three months ended September 30, 2023, was $0.80, compared to $0.79 for the same period in 2022, indicating a 1.3% increase[21] - Total operating expenses for the three months ended September 30, 2023, were $514.0 million, a decrease of 1.0% from $519.1 million in the same period last year[21] Expenses and Costs - The company incurred merger-related expenses of $5.0 million during the three months ended September 30, 2023[21] - Interest expense for the three months ended September 30, 2023, was $8.0 million, compared to $5.0 million for the same period in 2022, reflecting a 61.5% increase[21] - General and administrative expenses totaled $198.0 million, with home health at $91.4 million, hospice at $48.4 million, and high acuity care at $5.3 million[122] - The cost of service, including depreciation, amounted to $311.6 million, with home health at $201.6 million, hospice at $104.2 million, and high acuity care at $5.8 million[122] Cash Flow and Investments - Cash flows from operating activities for the nine months ended September 30, 2023, provided $76,877, compared to $92,400 for the same period in 2022[29] - The company reported a net cash increase of $39,883 for the nine months ended September 30, 2023[29] - The company made investments in technology assets totaling $6,881 during the nine months ended September 30, 2023[29] - The company has $550.0 million available under its Revolving Credit Facility, with $517.4 million available as of September 30, 2023[103] Revenue Sources - Approximately 73% of consolidated net service revenue for the three and nine-month periods ended September 30, 2023, was derived from Medicare, slightly down from 74% in the same periods of 2022[33] - For the three-month period ended September 30, 2023, Medicare revenue represented 39% of home health revenue, consistent with the same period in 2022[49] - Non-Medicare episodic-based revenue accounted for 7% of home health revenue for the three-month period ended September 30, 2023, unchanged from the same period in 2022[49] - Non-Medicare non-episodic-based revenue increased to 17% of home health revenue for the three-month period ended September 30, 2023, up from 13% in the same period of 2022[49] Mergers and Acquisitions - The company entered into a merger agreement with UnitedHealth Group on June 26, 2023, with Amedisys continuing as a wholly owned subsidiary[34] - Amedisys paid a termination fee of $106 million to Option Care Health, Inc. as part of the termination of a previous merger agreement, which was recorded as other income[82] - The company acquired regulatory assets of a home health provider for $0.4 million on January 20, 2023, recording $0.3 million in goodwill[84] - Goodwill recorded from the 2022 acquisition will be deductible for income tax purposes over approximately two to five years[87] Divestitures - The company divested its personal care business on March 31, 2023, which previously contributed to its revenue[33] - The company divested its personal care business for net proceeds of $47.8 million, recognizing a loss of $2.2 million during the three-month period ended March 31, 2023[93] Assets and Liabilities - The total balance as of September 30, 2023, was $1,093,518, with retained earnings of $728,603[26] - The total current assets decreased to $15.7 million as of September 30, 2023, from $22.3 million as of December 31, 2022, representing a decline of 29.66%[80] - Total assets decreased to $24.9 million as of September 30, 2023, compared to $31.6 million as of December 31, 2022, indicating a reduction of 21.43%[80] - Current liabilities increased to $8.1 million as of September 30, 2023, from $6.7 million as of December 31, 2022, marking a rise of 20.90%[80] Legal and Compliance - The company is involved in ongoing legal actions, but does not anticipate a material impact on its financial condition from these matters[108] - The company maintains various insurance programs but is self-insured for a substantial portion of potential claims, with exposure limits set for different types of insurance[115] Shareholder Information - The company repurchased 150,000 shares at a weighted average price of $115.64 per share, totaling approximately $17 million during the nine-month period ended September 30, 2022[128] - The 2023 Share Repurchase Program allows for up to $100 million in stock repurchases, with no shares repurchased as of September 30, 2023[128] - The company has not repurchased any shares under the 2023 Share Repurchase Program due to merger agreement limitations[128]

Exhibit 99.1 AMEDISYS REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS BATON ROUGE, Louisiana (October 24, 2023) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and ninemonth periods ended September 30, 2023. Three-Month Periods Ended September 30, 2023 and 2022 ◦ Net service revenue decreased $1.8 million to $556.2 million compared to $558.0 million in 2022. Prior year included $16.6 million of net service revenue from our personal care business which was divested on March 31 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AMED The NASDAQ Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECUR ...

Financial Performance - For the three-month period ended March 31, 2023, consolidated net service revenue was $556.4 million, an increase from $545.3 million in the same period of 2022, representing a year-over-year growth of approximately 2.0%[121] - Operating income decreased by $6 million to $42.4 million, impacted by the return of sequestration and acquisitions, despite an $11 million increase in net service revenue[122] - The hospice segment, which contributed significantly to revenue, is expected to see a 3.8% increase in payments for fiscal year 2023, based on CMS updates[115] - Net service revenue in the Home Health Segment increased by $8 million, with a 5% total volume growth[128] - Operating income in the Home Health Segment decreased by $10 million despite an $8 million increase in net service revenue[127] - Operating income in the Hospice Segment increased by $9 million on flat net service revenue, positively impacted by increased reimbursement rates[134] - Net service revenue in the Hospice Segment remained flat, affected by the reinstatement of sequestration at 2% and a decline in average daily census[135] - Operating income in the Personal Care Segment increased by $1 million on a $1 million increase in net service revenue driven by rate increases[139] Expenses and Costs - General and administrative expenses increased by $10 million year-over-year, primarily due to clinical optimization initiatives and planned wage increases[122] - General and administrative expenses in the Home Health Segment increased by $6 million, primarily due to planned wage increases and higher IT fees[130] - Total cost of service in the Home Health Segment increased by 6%, driven by a 3% increase in total cost per visit and total visits[129] - Interest expense increased by $4 million year over year due to higher interest rates on outstanding term loan borrowings[123] - Corporate general and administrative expenses increased by $7 million to $50.9 million for the three-month period ended March 31, 2023, compared to $43.5 million in the same period of 2022[149] Cash Flow and Financing - Cash provided by operating activities decreased by $22.6 million to $26.0 million for the three-month period ended March 31, 2023, compared to $48.6 million in the same period of 2022[151] - Cash used in financing activities totaled $(56.9) million for the three-month period ended March 31, 2023, compared to $(7.4) million in the same period of 2022, primarily due to repayment of borrowings[153] - Cash, cash equivalents, and restricted cash at the end of the period were $69.1 million as of March 31, 2023, compared to $70.9 million at the end of the same period in 2022[151] - The company had no outstanding borrowings under its $550.0 million Revolving Credit Facility, with availability at $519.2 million[160] - The weighted average interest rate for borrowings under the Amended Term Loan Facility was 6.1% for the three-month period ended March 31, 2023, compared to 1.7% for the same period in 2022[160] - The consolidated leverage ratio as of March 31, 2023, was 1.6, and the consolidated interest coverage ratio was 10.3[160] Strategic Developments - The company announced a proposed merger with Option Care Health, with an exchange ratio of 3.0213 shares of Option Care Health common stock for each share of Amedisys common stock[111] - The company appointed Richard Ashworth as President and CEO effective April 10, 2023, following the departure of Paul B. Kusserow from the CEO position[113] - The company expects capital expenditures and investments in technology assets for 2023 to be approximately $17.0 million to $18.0 million, excluding future acquisitions[154] - The company has authorized a new share repurchase program of up to $100 million through December 31, 2023, with no shares repurchased as of March 31, 2023[161] Operational Metrics - As of March 31, 2023, the company operated 348 Medicare-certified home health care centers and 165 Medicare-certified hospice care centers, with a total of 9 admitting high acuity care joint ventures[109] - Average Medicare revenue per completed episode decreased to $2,974 from $3,013 year over year[125] - Hospice admissions decreased by 5% year over year, impacting overall performance[134] - Total admissions increased to 617 in the three-month period ended March 31, 2023, compared to 333 in the same period of 2022, reflecting an increase of 85%[141] - Operating loss for the high acuity care segment was $(6.0) million for the three-month period ended March 31, 2023, compared to $(5.0) million in the same period of 2022[141] - Days revenue outstanding increased to 46.3 days as of March 31, 2023, compared to 46.1 days at December 31, 2022[155] - Total patient accounts receivable was $294.1 million as of March 31, 2023, down from $296.8 million at December 31, 2022[157] Economic Impact - Inflation has materially impacted operations, with higher labor and supply costs, although some impacts have been mitigated by rate increases and clinical optimization initiatives[162] - The total amount of outstanding debt subject to interest rate fluctuations was $383.1 million as of March 31, 2023, with a 1.0% interest rate change potentially affecting annual interest expense by approximately $3.8 million[165]